Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1,Condition 2a,Condition 2b,Condition 3 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0000716,blood vessel contractile force measurement,,,,1.59,g,0.11,0.3811,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,,,,,Kreb's solution perfusate then potassium chloride solution (40 mmol/l) ,69048,Kreb's solution perfusate,potassium chloride solution (40 mmol/l) ,, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000903,SS.MNS-(D2Mit6-D2Rat303)/Ayd,male,98 days,13,,CMO:0000716,blood vessel contractile force measurement,,,,1.62,g,0.09,0.3245,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then potassium chloride solution (40 mmol/l) ,69049,Kreb's solution perfusate,potassium chloride solution (40 mmol/l) ,, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0000716,blood vessel contractile force measurement,,,,1.39,g,0.06,0.2078,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then potassium chloride solution (40 mmol/l) and NG-nitroarginine methyl ester (100 umol/l) ,69050,Kreb's solution perfusate,potassium chloride solution (40 mmol/l) ,NG-nitroarginine methyl ester (100 umol/l) , 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000903,SS.MNS-(D2Mit6-D2Rat303)/Ayd,male,98 days,13,,CMO:0000716,blood vessel contractile force measurement,,,,1.6,g,0.12,0.4327,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then potassium chloride solution (40 mmol/l) and NG-nitroarginine methyl ester (100 umol/l) ,69051,Kreb's solution perfusate,potassium chloride solution (40 mmol/l) ,NG-nitroarginine methyl ester (100 umol/l) , 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",arterial blood pressure trait,,RS:0000817,SS/Jr,male,98 days to 68 days,10,,CMO:0000009,mean arterial blood pressure,,,,170,mmHg,,,MMO:0000015,radiotelemetry,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69025,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",arterial blood pressure trait,,RS:0000889,SS.MNS-(D2Mit6-Adh1)/Ayd,male,98 days to 68 days,5,,CMO:0000009,mean arterial blood pressure,,,,120,mmHg,,,MMO:0000015,radiotelemetry,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69026,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",arterial blood pressure trait,,RS:0000901,SS.MNS-(D2Mit6-D2Rat166)/Ayd,male,98 days to 68 days,9,,CMO:0000009,mean arterial blood pressure,,,,148,mmHg,,,MMO:0000015,radiotelemetry,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69027,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",arterial blood pressure trait,,RS:0000903,SS.MNS-(D2Mit6-D2Rat303)/Ayd,male,98 days to 68 days,9,,CMO:0000009,mean arterial blood pressure,,,,168,mmHg,,,MMO:0000015,radiotelemetry,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69028,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",arterial blood pressure trait,,RS:0000906,SS.MNS-(Mme-D2Rat131)/Ayd,male,98 days to 68 days,5,,CMO:0000009,mean arterial blood pressure,,,,122,mmHg,,,MMO:0000015,radiotelemetry,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69029,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0000722,logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50),,EC50 value is probably moles/liter,,-7.26,,0.06,0.2078,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then phenylephrine (1-100 mmol/l) ,69054,Kreb's solution perfusate,phenylephrine (1-100 mmol/l) ,, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000903,SS.MNS-(D2Mit6-D2Rat303)/Ayd,male,98 days,13,,CMO:0000722,logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50),,EC50 value is probably moles/liter,,-6.96,,0.17,0.6129,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then phenylephrine (1-100 mmol/l) ,69055,Kreb's solution perfusate,phenylephrine (1-100 mmol/l) ,, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0000722,logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50),,EC50 value is probably moles/liter,,-7.6,,0.05,0.1732,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then phenylephrine (1-100 mmol/l) and NG-nitroarginine methyl ester (100 umol/l) ,69058,Kreb's solution perfusate,phenylephrine (1-100 mmol/l) ,NG-nitroarginine methyl ester (100 umol/l) , 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000903,SS.MNS-(D2Mit6-D2Rat303)/Ayd,male,98 days,13,,CMO:0000722,logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50),,EC50 value is probably moles/liter,,-7.41,,0.16,0.5769,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then phenylephrine (1-100 mmol/l) and NG-nitroarginine methyl ester (100 umol/l) ,69059,Kreb's solution perfusate,phenylephrine (1-100 mmol/l) ,NG-nitroarginine methyl ester (100 umol/l) , 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",blood vessel smooth muscle cell quantity,,RS:0000889,SS.MNS-(D2Mit6-Adh1)/Ayd,male,98 days,5,,CMO:0001646,aorta smooth muscle cell count per unit vessel length,,,,58,/um,9.0,20.1246,MMO:0000220,ex vivo light microscopy with digital image analysis,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69030,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",blood vessel smooth muscle cell quantity,,RS:0000901,SS.MNS-(D2Mit6-D2Rat166)/Ayd,male,98 days,8,,CMO:0001646,aorta smooth muscle cell count per unit vessel length,,/um - calculated aortic smooth muscle cell count,,170,/um,11.0,31.1127,MMO:0000220,ex vivo light microscopy with digital image analysis,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69031,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",blood vessel smooth muscle cell quantity,,RS:0000903,SS.MNS-(D2Mit6-D2Rat303)/Ayd,male,98 days,8,,CMO:0001646,aorta smooth muscle cell count per unit vessel length,,/um - calculated aortic smooth muscle cell count,,134,/um,21.0,59.397,MMO:0000220,ex vivo light microscopy with digital image analysis,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69032,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",blood vessel smooth muscle cell quantity,,RS:0000906,SS.MNS-(Mme-D2Rat131)/Ayd,male,98 days,4,,CMO:0001646,aorta smooth muscle cell count per unit vessel length,,/um - calculated aortic smooth muscle cell count,,71,/um,4.0,8.0,MMO:0000220,ex vivo light microscopy with digital image analysis,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69033,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",blood vessel smooth muscle cell quantity,,RS:0000817,SS/Jr,male,98 days,10,,CMO:0001646,aorta smooth muscle cell count per unit vessel length,,/um - calculated aortic smooth muscle cell count,,90,/um,4.0,12.6491,MMO:0000220,ex vivo light microscopy with digital image analysis,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69034,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",heart left ventricle DNA amount,,RS:0000889,SS.MNS-(D2Mit6-Adh1)/Ayd,male,98 days,5,,CMO:0001649,heart left ventricle deoxyribonucleic acid level to body weight ratio,,,,3,ug/g,0.2,0.4472,MMO:0000173,spectrophotometry,,0.0,DNA extraction method,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69035,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",heart left ventricle DNA amount,,RS:0000901,SS.MNS-(D2Mit6-D2Rat166)/Ayd,male,98 days,4,,CMO:0001649,heart left ventricle deoxyribonucleic acid level to body weight ratio,,,,5,ug/g,0.5,1.0,MMO:0000173,spectrophotometry,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69036,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",heart left ventricle DNA amount,,RS:0000903,SS.MNS-(D2Mit6-D2Rat303)/Ayd,male,98 days,5,,CMO:0001649,heart left ventricle deoxyribonucleic acid level to body weight ratio,,,,5,ug/g,0.5,1.118,MMO:0000173,spectrophotometry,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69037,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",heart left ventricle DNA amount,,RS:0000906,SS.MNS-(Mme-D2Rat131)/Ayd,male,98 days,5,,CMO:0001649,heart left ventricle deoxyribonucleic acid level to body weight ratio,,,,3.7,ug/g,0.3,0.6708,MMO:0000173,spectrophotometry,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69038,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",heart left ventricle DNA amount,,RS:0000817,SS/Jr,male,98 days,11,,CMO:0001649,heart left ventricle deoxyribonucleic acid level to body weight ratio,,,,5.8,ug/g,0.6,1.99,MMO:0000173,spectrophotometry,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69039,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0001656,receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio,,,,34.85,%,2.94,10.1845,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then angiotensin II (0.3-300 umol/l) ,69065,Kreb's solution perfusate,angiotensin II (0.3-300 umol/l) ,, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000903,SS.MNS-(D2Mit6-D2Rat303)/Ayd,male,98 days,13,,CMO:0001656,receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio,,,,19.33,%,3.67,13.2324,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then angiotensin II (0.3-300 umol/l) ,69066,Kreb's solution perfusate,angiotensin II (0.3-300 umol/l) ,, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0001656,receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio,,,,50.61,%,5.29,18.3251,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then angiotensin II (0.3-300 umol/l) and NG-nitroarginine methyl ester (100 umol/l) ,69069,Kreb's solution perfusate,angiotensin II (0.3-300 umol/l) ,NG-nitroarginine methyl ester (100 umol/l) , 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000903,SS.MNS-(D2Mit6-D2Rat303)/Ayd,male,98 days,13,,CMO:0001656,receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio,,,,26.63,%,4.0,14.4222,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then angiotensin II (0.3-300 umol/l) and NG-nitroarginine methyl ester (100 umol/l) ,69070,Kreb's solution perfusate,angiotensin II (0.3-300 umol/l) ,NG-nitroarginine methyl ester (100 umol/l) , 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0001656,receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio,,,,104.06,%,4.7,16.2813,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then phenylephrine (1-100 mmol/l) ,69052,Kreb's solution perfusate,phenylephrine (1-100 mmol/l) ,, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000903,SS.MNS-(D2Mit6-D2Rat303)/Ayd,male,98 days,13,,CMO:0001656,receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio,,,,100.16,%,5.63,20.2993,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then phenylephrine (1-100 mmol/l) ,69053,Kreb's solution perfusate,phenylephrine (1-100 mmol/l) ,, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0001656,receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio,,,,141.72,%,7.73,26.7775,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then phenylephrine (1-100 mmol/l) and NG-nitroarginine methyl ester (100 umol/l) ,69056,Kreb's solution perfusate,phenylephrine (1-100 mmol/l) ,NG-nitroarginine methyl ester (100 umol/l) , 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000903,SS.MNS-(D2Mit6-D2Rat303)/Ayd,male,98 days,13,,CMO:0001656,receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio,,,,143.03,%,6.62,23.8687,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then phenylephrine (1-100 mmol/l) and NG-nitroarginine methyl ester (100 umol/l) ,69057,Kreb's solution perfusate,phenylephrine (1-100 mmol/l) ,NG-nitroarginine methyl ester (100 umol/l) , 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0001658,logarithm of the concentration of angiotensin II at which the force of blood vessel contraction is half the maximum value (Log EC50),,,,-8.22,,0.26,0.9007,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then angiotensin II (0.3-300 umol/l) ,69067,Kreb's solution perfusate,angiotensin II (0.3-300 umol/l) ,, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000903,SS.MNS-(D2Mit6-D2Rat303)/Ayd,male,98 days,13,,CMO:0001658,logarithm of the concentration of angiotensin II at which the force of blood vessel contraction is half the maximum value (Log EC50),,,,-7.86,,0.27,0.9735,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then angiotensin II (0.3-300 umol/l) ,69068,Kreb's solution perfusate,angiotensin II (0.3-300 umol/l) ,, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000817,SS/Jr,male,98 days,12,,CMO:0001658,logarithm of the concentration of angiotensin II at which the force of blood vessel contraction is half the maximum value (Log EC50),,,,-7.92,,0.36,1.2471,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then angiotensin II (0.3-300 umol/l) then NG-nitroarginine methyl ester (100 umol/l) ,69071,Kreb's solution perfusate,angiotensin II (0.3-300 umol/l) ,,NG-nitroarginine methyl ester (100 umol/l) 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",vasoconstriction trait,,RS:0000903,SS.MNS-(D2Mit6-D2Rat303)/Ayd,male,98 days,13,,CMO:0001658,logarithm of the concentration of angiotensin II at which the force of blood vessel contraction is half the maximum value (Log EC50),,,,-7.2,,0.31,1.1177,MMO:0000207,tissue force analysis utilizing a force transducer,,0.0,isometric force transducer,,,,Kreb's solution perfusate then angiotensin II (0.3-300 umol/l) and NG-nitroarginine methyl ester (100 umol/l) ,69072,Kreb's solution perfusate,angiotensin II (0.3-300 umol/l) ,NG-nitroarginine methyl ester (100 umol/l) , 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",heart right ventricle DNA amount,,RS:0000889,SS.MNS-(D2Mit6-Adh1)/Ayd,male,98 days,5,,CMO:0001652,heart right ventricle deoxyribonucleic acid level to body weight ratio,,,,1.13,ug/g,0.05,0.1118,MMO:0000173,spectrophotometry,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69040,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",heart right ventricle DNA amount,,RS:0000901,SS.MNS-(D2Mit6-D2Rat166)/Ayd,male,98 days,4,,CMO:0001652,heart right ventricle deoxyribonucleic acid level to body weight ratio,,,,0.5,ug/g,0.09,0.18,MMO:0000173,spectrophotometry,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69041,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",heart right ventricle DNA amount,,RS:0000903,SS.MNS-(D2Mit6-D2Rat303)/Ayd,male,98 days,5,,CMO:0001652,heart right ventricle deoxyribonucleic acid level to body weight ratio,,,,1.2,ug/g,0.09,0.2012,MMO:0000173,spectrophotometry,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69042,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",heart right ventricle DNA amount,,RS:0000906,SS.MNS-(Mme-D2Rat131)/Ayd,male,98 days,5,,CMO:0001652,heart right ventricle deoxyribonucleic acid level to body weight ratio,,,,1.1,ug/g,0.2,0.4472,MMO:0000173,spectrophotometry,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69043,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),, 1096,"Dutil J, et al., Physiol Genomics 2005 Mar 1;.",heart right ventricle DNA amount,,RS:0000817,SS/Jr,male,98 days,11,,CMO:0001652,heart right ventricle deoxyribonucleic acid level to body weight ratio,,,,1.1,ug/g,0.1,0.3317,MMO:0000173,spectrophotometry,,0.0,,,,,controlled sodium content diet (0.2 %) (for 14 days) then controlled sodium content diet (2 %) (for 63 days),69044,controlled sodium content diet (0.2 %) (for 14 days),controlled sodium content diet (2 %) (for 63 days),,